Positive Treatment Results Seen in Patients with Active Crohn’s Disease at Week 12 of Study

Positive Treatment Results Seen in Patients with Active Crohn’s Disease at Week 12 of Study
Celgene Corporation has reported positive interim results from a Phase 1b clinical trial assessing the effects of oral GED-0301 (mongersen) on endoscopic and clinical outcomes in patients with active Crohn’s disease. The trial aims to provide further data of GED-0301 activity in a difficult-to-treat, moderate-to-severe and very diverse patient population, including patients with endoscopically confirmed mucosal

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *